Metastatic Melanoma: Clinical Trials

12 trials for Metastatic Melanoma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 terminated, 3 active not recruiting, 3 completed, 1 not yet recruiting. 12 Phase 3, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 312Terminated 4, Active not recruiting 3, Completed 3, Not yet recruiting 1, Recruiting 1
Phase 21Terminated 1

Follow Metastatic Melanoma: new trials by email Literature Review of Metastatic Melanoma trials Research Report on Metastatic Melanoma

Trials (filtered) newest first · largest first

All 12 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
iSCIB1+ in Combination With Ipilimumab and Nivolumab as First-Line Treatment for Advanced Unresectable Melanoma
iSCIB1+, Nivolumab & Ipilimumab, Placebo - Melanoma (Skin Cancer), Advanced Melanoma
Phase 3Not yet recruitingScancell Ltd5502026-12-012026-09-11
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
Computed Tomography, Fractionated Stereotactic Radiation Therapy, Magnetic Resonance Imaging - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma
Phase 3Active not recruitingNRG Oncology2742024-12-122026-09-14
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
Lifileucel plus Pembrolizumab, Pembrolizumab with Optional Crossover Period - Metastatic Melanoma, Unresectable Melanoma
Phase 3RecruitingIovance Biotherapeutics, Inc.6702023-03-302026-09-24
IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)
IO102-IO103, Pembrolizumab - Metastatic Melanoma, Unresectable Melanoma
Phase 3Active not recruitingIO Biotech4072022-05-172025-08-28
Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in Patients With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery
Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Lung Non-Small Cell Carcinoma
Phase 3TerminatedNRG Oncology192021-08-052026-05-20
CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced Melanoma
CMP-001, Nivolumab - Melanoma, Advanced Melanoma
Phase 2 / Phase 3TerminatedRegeneron Pharmaceuticals202021-02-242026-06-15
A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma
Ipilimumab, Tilsotolimod with Ipilimumab - Metastatic Melanoma
Phase 3TerminatedIdera Pharmaceuticals, Inc.4812018-05-302022-11-08
A Randomized, Controlled, Multi-center, Phase III Clinical Study to Investigate Recombinant Humanized PD-1 Monoclonal Antibody Injection (JS001) Versus Dacarbazine as the 1st-line Therapy for Unresectable or Metastatic Melanoma
JS001 240mg Q2W, Dacarbazine 1000mg/m2 Q3W - Metastatic Melanoma, Unresectable Melanoma
Phase 3CompletedShanghai Junshi Bioscience Co., Ltd.2562018-02-022024-09-19
Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma
Biospecimen Collection, Computed Tomography, Dabrafenib Mesylate - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8
Phase 3Active not recruitingNational Cancer Institute (NCI)2672015-09-082026-11-18
Study Comparing TIL to Standard Ipilimumab in Patients With Metastatic Melanoma
Translational research, Cyclophosphamide, Fludarabine - Metastatic Melanoma
Phase 3CompletedThe Netherlands Cancer Institute1682014-09-232025-03-10
Masitinib in Non-Resectable or Metastatic Stage 3/4 Melanoma Carrying a Mutation in the Juxta Membrane Domain of c-Kit
Masitinib, Dacarbazine - Metastatic Melanoma
Phase 3TerminatedAB Science1342011-01-012020-11-05
A Phase 3 Pivotal Trial Comparing Allovectin-7® Alone vs Chemotherapy Alone in Patients With Stage 3 or Stage 4 Melanoma
Allovectin-7®, Dacarbazine (DTIC), Temozolomide (TMZ) - Metastatic Melanoma
Phase 3CompletedVical3902006-10-012013-09-13

Narrower conditions

Melanoma (12)  ·  Neoplasm Metastasis (4)  ·  Skin Neoplasms (3)  ·  Brain Neoplasms (2)  ·  Breast Neoplasms (2)  ·  Carcinoma, Non-Small-Cell Lung (2)  ·  Carcinoma, Renal Cell (2)  ·  Lung Neoplasms (2)  ·  Diabetes Mellitus, Insulin-Dependent, 12 (1)  ·  Gastrointestinal Neoplasms (1)  ·  Small Cell Lung Carcinoma (1)

Broader conditions

Neoplasms (12)  ·  Neoplasms by Histologic Type (12)  ·  Neoplasms by Site (12)  ·  Neoplasms, Germ Cell and Embryonal (12)  ·  Neoplasms, Nerve Tissue (12)  ·  Neuroectodermal Tumors (12)  ·  Neuroendocrine Tumors (12)  ·  Nevi and Melanomas (12)  ·  Skin Diseases (12)  ·  Skin and Connective Tissue Diseases (12)  ·  Skin Neoplasms (9)  ·  Neoplastic Processes (4)  ·  Pathologic Processes (4)  ·  Pathological Conditions, Signs and Symptoms (4)  ·  Adenocarcinoma (2)

Interventions

Dacarbazine (3)  ·  Ipilimumab (3)  ·  Nivolumab (3)  ·  Magnetic Resonance Spectroscopy (2)  ·  Radiosurgery (2)  ·  Specimen Handling (2)  ·  pembrolizumab (2)  ·  Allovectin-7 (1)  ·  Blood Specimen Collection (1)  ·  CTLA-4 Antigen (1)  ·  Cyclophosphamide (1)  ·  Drug Therapy (1)  ·  Interleukin-2 (1)  ·  Memantine (1)  ·  Temozolomide (1)

Sponsors

NRG Oncology (2)  ·  AB Science (1)  ·  IO Biotech (1)  ·  Idera Pharmaceuticals, Inc. (1)  ·  Iovance Biotherapeutics, Inc. (1)  ·  National Cancer Institute (NCI) (1)  ·  Regeneron Pharmaceuticals (1)  ·  Scancell Ltd (1)  ·  Shanghai Junshi Bioscience Co., Ltd. (1)  ·  The Netherlands Cancer Institute (1)  ·  Vical (1)

Countries

United States (10)  ·  Canada (5)  ·  France (5)  ·  Germany (5)  ·  Italy (5)  ·  Netherlands (5)  ·  Spain (5)  ·  United Kingdom (4)  ·  Australia (3)  ·  Belgium (3)  ·  Czechia (3)  ·  Israel (3)  ·  Denmark (2)  ·  Hong Kong (2)  ·  Poland (2)

Top investigators

Inge Marie Svane, MD, Prof (1)  ·  Jun Guo (1)  ·  Linda Strause, PhD (1)  ·  Michael B Atkins (1)  ·  Rupesh R Kotecha (1)  ·  Vinai Gondi (1)

Results publications

PMID 29784747, PMID 36166727, PMID 36477031, PMID 40048691, PMID 40474841, PMID 40541863, PMID 41481311

NIH funding

U10CA180868 (2), U10CA180820 (1)